CN Patent

CN104936589A — 具有改善的生物利用度的药物组合物

Assigned to F Hoffmann La Roche AG · Expires 2015-09-23 · 11y expired

What this patent protects

本发明涉及通过溶剂共沉淀或喷雾干燥形成的水难溶性化合物，特别是4-{[(2R,3S,4R,5S)-4-(4-氯-2-氟苯基)-3-(3-氯-2-氟苯基)-4-氰基-5-(2,2-二甲基丙基)-吡咯烷-2-羰基]氨基}-3-甲氧基-苯甲酸的固体分散体，其导致所述化合物的改善的生物利用度、安全性和耐受性。

USPTO Abstract

本发明涉及通过溶剂共沉淀或喷雾干燥形成的水难溶性化合物，特别是4-{[(2R,3S,4R,5S)-4-(4-氯-2-氟苯基)-3-(3-氯-2-氟苯基)-4-氰基-5-(2,2-二甲基丙基)-吡咯烷-2-羰基]氨基}-3-甲氧基-苯甲酸的固体分散体，其导致所述化合物的改善的生物利用度、安全性和耐受性。

Drugs covered by this patent

Patent Metadata

Patent number
CN104936589A
Jurisdiction
CN
Classification
—
Expires
2015-09-23
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.